Compositions and methods for immune cell modulation in adoptive immunotherapies

Patent metadata

Field	Value
Publication number	US-12419870-B2
Application number	US-202217861042-A
Country	US
Kind code	B2
Filing date	Jul 8, 2022
Priority date	Jan 20, 2016
Publication date	Sep 23, 2025
Grant date	Sep 23, 2025

Abstract

Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.

First claim

What is claimed is:

1. A composition, wherein the composition is a culture medium comprising a combination,
wherein the combination comprises (a) a mammalian target of rapamycin (mTOR) inhibitor, and (b) dimethyl prostaglandin E2 (dmPGE2) or an analogue or derivative thereof; and
wherein the combination is present in an amount effective to modulate a population of T cells to (a) reduce expression of one or more T cell exhaustion markers, or (b) increase mitochondrial spare respiratory capacity, in comparison to a corresponding population of T cells that are not modulated with the combination.

2. The composition of claim 1 , wherein the one or more T cell exhaustion markers comprise one or more of PD-1 and Tim-3.

3. The composition of claim 1 , wherein the combination is present in an amount effective to (a) increase a central memory T cell subpopulation of the population of T cells, and (b) decrease an effector T cell subpopulation of the population of T cells.

4. The composition of claim 1 , further comprising the population of T cells.

5. The composition of claim 4 , wherein the population of T cells comprises (a) increased gene expression in at least one of CD27, C-C chemokine receptor type 7 (CCR7), CD62L, transcription factor 7 (TCF7), lymphoid enhancer-binding factor 1 (LEF1), and (b) decreased gene expression in at least one of PR domain zinc finger protein 1 (BLIMP-1), fructose-bisphosphate aldolase C (ALDOC), gamma enolase (ENO2), PD-1 and Tim-3, in comparison to a corresponding population of T cells that are not modulated with the combination.

6. The composition of claim 4 , wherein the population of T cells comprises increased spare respiratory capacity (SRC) in comparison to a corresponding population of T cells that are not modulated with the composition.

7. The composition of claim 4 , wherein the population of T cells comprises at least one of the following:
(a) increased gene expression in at least one of CD27, CCR7, CD62L, TCF7, and LEF1;
(b) decreased gene expression in at least one of BLIMP-1, ALDOC, ENO2, and PGK1;
(c) increased central memory T cell subpopulation;
(d) decreased effector T cell subpopulation; and
(e) improved capability in tumor clearance and persistence;
compared to a corresponding population of T cells that are not modulated with the composition.

8. The composition of claim 4 , wherein T cells of the population of T cells comprise at least one genetic modification.

9. The composition of claim 8 , wherein the at least one genetic modification comprises an insertion, a deletion, or a nucleic acid replacement.

10. The composition of claim 8 , wherein the at least one genetic modification comprises an exogenous nucleic acid encoding a T Cell Receptor (TCR) and/or a Chimeric Antigen Receptor (CAR).

11. The composition of claim 8 , wherein the at least one genetic modification comprises insertion or modification of a sequence encoding at least one of a safety switch protein, a targeting modality, a receptor, a signaling molecule, a transcription factor, a pharmaceutically active protein or peptide, a drug target candidate, or a protein promoting one or more activities; wherein the one or more activities comprise one or more of engraftment, trafficking, homing, viability, self-renewal, persistence, immune response regulation and modulation, and survival of the T cells.

12. The composition of claim 8 , wherein the at least one genetic modification comprises deletion or reduced expression of B2M, TAP1, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, CIITA, RFX5, or RFXAP, or any gene in the chromosome 6p21 region.

13. The composition of claim 8 , wherein the at least one genetic modification comprises introduced or increased expression of HLA-E, HLA-G, HACD16, hnCD16, 41BBL, CD3, CD4, CD8, CD47, CD113, CD131, CD137, CD80, PDL1, A2AR, Fc receptor, or surface triggering receptors for coupling with bi- or multi-specific or universal engagers.

14. The composition of claim 8 , wherein the population of T cells are differentiated in vitro from stem cells, hematopoietic stem or progenitor cells, or progenitor cells; and wherein the stem cells, hematopoietic stem or progenitor cells, or progenitor cells comprise the at least one genetic modification.

15. The composition of claim 14 , wherein the stem cells comprise induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs).

16. The composition of claim 14 , wherein the progenitor cells are CD34+ hemogenic endothelium cells, multipotent progenitor cells, or T cell progenitor cells.

Assignees

• Fate Therapeutics Inc

Inventors

• Rosen Jonathan
• Rezner Betsy
• Valamehr Bahram
• Bjordahl Ryan
• Peralta Eigen
• Hardy Ian

Classifications

• A61K40/42

  Cancer antigens · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title